Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.

Alimentary pharmacology & therapeutics·2018
Same author

Clinical experience with abciximab during coronary revascularisation: an overview.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.

Heart (British Cardiac Society)·2006
Same author

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

Journal of thrombosis and haemostasis : JTH·2004
Same author

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.

European heart journal·2004

相关实验视频

Updated: Jun 19, 2026

A Plate Competition Assay As a Quick Preliminary Assessment of Disease Suppression
05:23

A Plate Competition Assay As a Quick Preliminary Assessment of Disease Suppression

Published on: October 28, 2018

在美国,通过抑制血小板糖蛋白IIb/IIIa来治疗急性冠状动脉综合征患者. 在不稳定的心痛中血小板糖蛋白IIb/IIIa的洞察力:使用整合林治疗抑制受体 (PURSUIT) 试验.

A M Lincoff1, R A Harrington, R M Califf

  • 1Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Circulation
|September 7, 2000
PubMed
概括

作为糖蛋白IIb/IIIa抑制剂的eptifibatide显著减少了美国急性缺血综合征患者的死亡或心肌梗塞. 这种益处在早期观察到,持续了六个月,主要与手术相关的出血风险增加.

更多相关视频

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

相关实验视频

Last Updated: Jun 19, 2026

A Plate Competition Assay As a Quick Preliminary Assessment of Disease Suppression
05:23

A Plate Competition Assay As a Quick Preliminary Assessment of Disease Suppression

Published on: October 28, 2018

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学 是一个学科.
  • 临床试验 临床试验

背景情况:

  • 跨国PURSUIT试验确定了eptifibatide在急性缺血综合征中有效性,而没有ST段升高.
  • 一个小组分析侧重于美国的患者,以评估区域实践模式的影响.
  • 埃皮菲巴提德是一种血小板糖蛋白IIb/IIIa受体对抗剂.

研究的目的:

  • 为了评估eptifibatide在PURSUIT试验中的美国患者队列中的有效性.
  • 评估美国患者治疗eptifibatide的死亡或心肌梗塞的发生率.

主要方法:

  • 随机的,安慰剂控制的试验设计.
  • 美国有4035名患者接受了安慰剂或提巴提德输液 (72-96小时).
  • 资格标准包括24小时内胸部疼痛和缺血性心电图变化或肌酸酶-MB升高.

主要成果:

  • 在美国患者中,eptifibatide 从15.4%降低到11.9% (P=0.003) 的初级终点 (死亡或心肌梗塞30天).
  • 治疗效果在6个月后显著 (18.9%对15.2%;P=0.004).
  • 随着eptifibatide的使用,出血事件增加,主要与侵入性手术有关.

结论:

  • 提巴提德显著降低了在美国患有急性缺血综合征而没有ST段升高的患者中死亡或心肌梗塞的发生率.
  • 与全球数据相比,eptifibatide在美国患者小组中的临床益处更为明显.